Assessment of potential drug-drug interactions with a prescription claims database

Daniel C Malone, David S. Hutchins, Heather Haupert, Philip Hansten, Babette Duncan, Robin C. Van Bergen, Steve L. Solomon, Richard B. Lipton

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Purpose. The prevalence of 25 clinically important potential drug-drug interactions (DDIs) in a population represented by the drug claims database of a pharmacy benefit management company (PBM) was studied. Methods. A retrospective cross-sectional analysis of pharmaceutical claims for almost 46 million participants in a PBM was conducted to determine the frequency of 25 DDIs previously identified as clinically important. A DDI was counted when drugs in potentially interacting combinations were dispensed within 30 days of each other during a 25-month period between April 2000 and June 2002. Results. The number of DDIs ranged from 37 for pimozide and an azole antifungal to 127,684 for warfarin and a nonsteroidal antiinflammatory drug (NSAID). The highest prevalence (278.56 per 100,000 persons) and highest case-exposure rate (242.7 per 1,000 warfarin recipients) occurred with the warfarin-NSAID combination. The combination with the lowest overall prevalence (cyclosporine and a rifamycin, 0.10/100,000) differed from the combination with the lowest case-exposure rate (pimozide and an azole antifungal, 0.028 per 1,000 azole antifungal recipients). Number of cases, prevalence, and case-exposure rates for both sexes generally increased with age. An estimated 374,000 plan participants were exposed to a clinically important DDI during a 25-month period. Between 20% and 46% of prescription drug claims were reversed (canceled) for a medication with a drug interaction when a warning about the interaction was sent to the pharmacy. Conclusion. Analysis of prescription claims data from a major PBM found that 374,000 of 46 million plan participants had been exposed to a potential DDI of clinical importance.

Original languageEnglish (US)
Pages (from-to)1983-1991
Number of pages9
JournalAmerican Journal of Health-System Pharmacy
Volume62
Issue number19
DOIs
StatePublished - Oct 1 2005

Fingerprint

Drug Interactions
Prescriptions
Databases
Pharmaceutical Preparations
Azoles
Warfarin
Pimozide
Anti-Inflammatory Agents
Pharmaceutical Databases
Insurance Claim Review
Prescription Drugs
Drug Combinations
Cyclosporine
Cross-Sectional Studies
Population

Keywords

  • Age
  • Anticoagulants
  • Antifungals
  • Antiinflammatory agents
  • Antipsychotic agents
  • Cyclosporine
  • Drug interactions
  • Immunosuppressive agents
  • Interventions
  • Pharmacy benefit management companies
  • Pimozide
  • Prescriptions
  • Rifamycins
  • Toxicity
  • Warfarin

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Malone, D. C., Hutchins, D. S., Haupert, H., Hansten, P., Duncan, B., Van Bergen, R. C., ... Lipton, R. B. (2005). Assessment of potential drug-drug interactions with a prescription claims database. American Journal of Health-System Pharmacy, 62(19), 1983-1991. https://doi.org/10.2146/ajhp040567

Assessment of potential drug-drug interactions with a prescription claims database. / Malone, Daniel C; Hutchins, David S.; Haupert, Heather; Hansten, Philip; Duncan, Babette; Van Bergen, Robin C.; Solomon, Steve L.; Lipton, Richard B.

In: American Journal of Health-System Pharmacy, Vol. 62, No. 19, 01.10.2005, p. 1983-1991.

Research output: Contribution to journalArticle

Malone, DC, Hutchins, DS, Haupert, H, Hansten, P, Duncan, B, Van Bergen, RC, Solomon, SL & Lipton, RB 2005, 'Assessment of potential drug-drug interactions with a prescription claims database', American Journal of Health-System Pharmacy, vol. 62, no. 19, pp. 1983-1991. https://doi.org/10.2146/ajhp040567
Malone, Daniel C ; Hutchins, David S. ; Haupert, Heather ; Hansten, Philip ; Duncan, Babette ; Van Bergen, Robin C. ; Solomon, Steve L. ; Lipton, Richard B. / Assessment of potential drug-drug interactions with a prescription claims database. In: American Journal of Health-System Pharmacy. 2005 ; Vol. 62, No. 19. pp. 1983-1991.
@article{987a67f8757c4de58098ed0c1c6a643b,
title = "Assessment of potential drug-drug interactions with a prescription claims database",
abstract = "Purpose. The prevalence of 25 clinically important potential drug-drug interactions (DDIs) in a population represented by the drug claims database of a pharmacy benefit management company (PBM) was studied. Methods. A retrospective cross-sectional analysis of pharmaceutical claims for almost 46 million participants in a PBM was conducted to determine the frequency of 25 DDIs previously identified as clinically important. A DDI was counted when drugs in potentially interacting combinations were dispensed within 30 days of each other during a 25-month period between April 2000 and June 2002. Results. The number of DDIs ranged from 37 for pimozide and an azole antifungal to 127,684 for warfarin and a nonsteroidal antiinflammatory drug (NSAID). The highest prevalence (278.56 per 100,000 persons) and highest case-exposure rate (242.7 per 1,000 warfarin recipients) occurred with the warfarin-NSAID combination. The combination with the lowest overall prevalence (cyclosporine and a rifamycin, 0.10/100,000) differed from the combination with the lowest case-exposure rate (pimozide and an azole antifungal, 0.028 per 1,000 azole antifungal recipients). Number of cases, prevalence, and case-exposure rates for both sexes generally increased with age. An estimated 374,000 plan participants were exposed to a clinically important DDI during a 25-month period. Between 20{\%} and 46{\%} of prescription drug claims were reversed (canceled) for a medication with a drug interaction when a warning about the interaction was sent to the pharmacy. Conclusion. Analysis of prescription claims data from a major PBM found that 374,000 of 46 million plan participants had been exposed to a potential DDI of clinical importance.",
keywords = "Age, Anticoagulants, Antifungals, Antiinflammatory agents, Antipsychotic agents, Cyclosporine, Drug interactions, Immunosuppressive agents, Interventions, Pharmacy benefit management companies, Pimozide, Prescriptions, Rifamycins, Toxicity, Warfarin",
author = "Malone, {Daniel C} and Hutchins, {David S.} and Heather Haupert and Philip Hansten and Babette Duncan and {Van Bergen}, {Robin C.} and Solomon, {Steve L.} and Lipton, {Richard B.}",
year = "2005",
month = "10",
day = "1",
doi = "10.2146/ajhp040567",
language = "English (US)",
volume = "62",
pages = "1983--1991",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "19",

}

TY - JOUR

T1 - Assessment of potential drug-drug interactions with a prescription claims database

AU - Malone, Daniel C

AU - Hutchins, David S.

AU - Haupert, Heather

AU - Hansten, Philip

AU - Duncan, Babette

AU - Van Bergen, Robin C.

AU - Solomon, Steve L.

AU - Lipton, Richard B.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Purpose. The prevalence of 25 clinically important potential drug-drug interactions (DDIs) in a population represented by the drug claims database of a pharmacy benefit management company (PBM) was studied. Methods. A retrospective cross-sectional analysis of pharmaceutical claims for almost 46 million participants in a PBM was conducted to determine the frequency of 25 DDIs previously identified as clinically important. A DDI was counted when drugs in potentially interacting combinations were dispensed within 30 days of each other during a 25-month period between April 2000 and June 2002. Results. The number of DDIs ranged from 37 for pimozide and an azole antifungal to 127,684 for warfarin and a nonsteroidal antiinflammatory drug (NSAID). The highest prevalence (278.56 per 100,000 persons) and highest case-exposure rate (242.7 per 1,000 warfarin recipients) occurred with the warfarin-NSAID combination. The combination with the lowest overall prevalence (cyclosporine and a rifamycin, 0.10/100,000) differed from the combination with the lowest case-exposure rate (pimozide and an azole antifungal, 0.028 per 1,000 azole antifungal recipients). Number of cases, prevalence, and case-exposure rates for both sexes generally increased with age. An estimated 374,000 plan participants were exposed to a clinically important DDI during a 25-month period. Between 20% and 46% of prescription drug claims were reversed (canceled) for a medication with a drug interaction when a warning about the interaction was sent to the pharmacy. Conclusion. Analysis of prescription claims data from a major PBM found that 374,000 of 46 million plan participants had been exposed to a potential DDI of clinical importance.

AB - Purpose. The prevalence of 25 clinically important potential drug-drug interactions (DDIs) in a population represented by the drug claims database of a pharmacy benefit management company (PBM) was studied. Methods. A retrospective cross-sectional analysis of pharmaceutical claims for almost 46 million participants in a PBM was conducted to determine the frequency of 25 DDIs previously identified as clinically important. A DDI was counted when drugs in potentially interacting combinations were dispensed within 30 days of each other during a 25-month period between April 2000 and June 2002. Results. The number of DDIs ranged from 37 for pimozide and an azole antifungal to 127,684 for warfarin and a nonsteroidal antiinflammatory drug (NSAID). The highest prevalence (278.56 per 100,000 persons) and highest case-exposure rate (242.7 per 1,000 warfarin recipients) occurred with the warfarin-NSAID combination. The combination with the lowest overall prevalence (cyclosporine and a rifamycin, 0.10/100,000) differed from the combination with the lowest case-exposure rate (pimozide and an azole antifungal, 0.028 per 1,000 azole antifungal recipients). Number of cases, prevalence, and case-exposure rates for both sexes generally increased with age. An estimated 374,000 plan participants were exposed to a clinically important DDI during a 25-month period. Between 20% and 46% of prescription drug claims were reversed (canceled) for a medication with a drug interaction when a warning about the interaction was sent to the pharmacy. Conclusion. Analysis of prescription claims data from a major PBM found that 374,000 of 46 million plan participants had been exposed to a potential DDI of clinical importance.

KW - Age

KW - Anticoagulants

KW - Antifungals

KW - Antiinflammatory agents

KW - Antipsychotic agents

KW - Cyclosporine

KW - Drug interactions

KW - Immunosuppressive agents

KW - Interventions

KW - Pharmacy benefit management companies

KW - Pimozide

KW - Prescriptions

KW - Rifamycins

KW - Toxicity

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=26244451620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244451620&partnerID=8YFLogxK

U2 - 10.2146/ajhp040567

DO - 10.2146/ajhp040567

M3 - Article

VL - 62

SP - 1983

EP - 1991

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 19

ER -